Presentation is loading. Please wait.

Presentation is loading. Please wait.

Hepatology may have problems with putative surrogate outcome measures

Similar presentations


Presentation on theme: "Hepatology may have problems with putative surrogate outcome measures"— Presentation transcript:

1 Hepatology may have problems with putative surrogate outcome measures
Christian Gluud, Jesper Brok, Yan Gong, Ronald L. Koretz  Journal of Hepatology  Volume 46, Issue 4, Pages (April 2007) DOI: /j.jhep Copyright © 2007 European Association for the Study of the Liver Terms and Conditions

2 Fig. 1 Basics of validation of a potential surrogate outcome measure (I). In order to function as a potential surrogate, the treatment (TR) must be instituted before the surrogate outcome measure (SO) is evaluated. Further, the evaluation of the surrogate outcome measure must occur before measuring the clinical outcome (CO). Based on Buyse et al. [2]. [This figure appears in colour on the web.] Journal of Hepatology  , DOI: ( /j.jhep ) Copyright © 2007 European Association for the Study of the Liver Terms and Conditions

3 Fig. 2 Basics of validation of a potential surrogate outcome measure (II). In order to function as a potential surrogate, the surrogate outcome measure (SO) must be correlated to the clinical outcome measure (CO). This can be shown in an observational study or in a randomised trial. When the correlation is established it is time to go to the next step in the validation of the potential surrogate for the offered treatment (TR): please see Fig. 3. Based on Buyse et al. [2]. [This figure appears in colour on the web.] Journal of Hepatology  , DOI: ( /j.jhep ) Copyright © 2007 European Association for the Study of the Liver Terms and Conditions

4 Fig. 3 Basics of validation of a potential surrogate outcome measure (III). In order to become a validated surrogate outcome measure for the offered treatment (TR) randomised trials ought to establish that the treatment has significant beneficial effects on the potential surrogate outcome measure (SO) and the clinical outcome measure (CO). The evaluation of the surrogate outcome and the clinical outcome measure is best performed based on data from meta-analyses of several randomised trials on the topic. Based on Buyse et al. [2]. [This figure appears in colour on the web.] Journal of Hepatology  , DOI: ( /j.jhep ) Copyright © 2007 European Association for the Study of the Liver Terms and Conditions


Download ppt "Hepatology may have problems with putative surrogate outcome measures"

Similar presentations


Ads by Google